905-P: Is Continuous Glucose Monitoring Effective? Evidence from Real-World Data

• Published in: Diabetes (New York, N.Y.) Vol. 69; no. Supplement_1
• Main Authors: ZHENG, YAGUANG, SIMINERIO, LINDA M., ANTON, BONNIE, KRALL, JODI T., BEDNARZ, LORI L., LI, DAN, NG, JASON
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2020
• Subjects: Clinical trials; Diabetes; Diabetes mellitus (non-insulin dependent); Electronic medical records; Glucose monitoring
• DOI: 10.2337/db20-905-P
• ISSN: 0012-1797

Background: Numerous clinical trials have shown the effectiveness of Continuous Glucose Monitoring (CGM) on glycemic control in patients with diabetes; however, real-world evidence of application of CGM is largely lacking. This retrospective study aimed to examine the effects of application of CGM in clinical practice. Method: Electronic health record (EHR) data from an integrated academic health center’s ambulatory diabetes clinic between May 2014 and May 2019 were used to identify eligible patients diagnosed with diabetes and had used CGM. Diabetes was defined based on ICD-10 Diagnosis Codes. Linear mixed models were used for analysis. Results: The sample (n=60) was White (86.7%), female (51.7%), with a mean age of 46.9±15.6 years and mean duration of diabetes 19.8±12.4 years. A total of 66.7% of sample had type 1 and 30.0% had type 2 diabetes. The types of CGM were intermittently scanned (51.7%), real-time (36.7%), and passive (11.6%). The HbA1c (%) had a significant reduction after CGM use at 3 months (7.76±1.53) and 6 months (7.76±1.83) compared with 3 months (8.53±1.91) and 6 months (8.62±1.80) before CGM use (p=.002). There were no differences in HbA1c changes by types of CGM (p=.31). Conclusion: Using EHR data can provide real-world evidence of CGM’s positive impact on glycemic control and on sustained improvement at 6 months. Future research should examine CGM effect gathered from multiple clinics. Disclosure Y. Zheng: None. L.M. Siminerio: Research Support; Self; Becton, Dickinson and Company. B. Anton: None. J.T. Krall: Research Support; Self; Becton, Dickinson and Company. L.L. Bednarz: Other Relationship; Self; Medtronic, Tandem Diabetes Care. D. Li: None. J. Ng: None.